Patricia Dickson

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Costello syndrome with pancreatic islet cell hyperplasia
    Patricia I Dickson
    Division of Medical Genetics, Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Am J Med Genet A 130:402-5. 2004
  2. ncbi Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid
    Patricia Dickson
    Division of Medical Genetics, Department of Pediatrics, LA Biomed at Harbor UCLA, Torrance, CA 90502, USA
    Mol Genet Metab 91:61-8. 2007
  3. ncbi Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients
    Patricia I Dickson
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Curr Pharm Biotechnol 12:946-55. 2011
  4. ncbi Research challenges in central nervous system manifestations of inborn errors of metabolism
    P I Dickson
    Department of Pediatrics, LA Biomedical Research Institute at Harbor UCLA, 1124 W Carson St, HH1, Torrance, CA 90502, USA
    Mol Genet Metab 102:326-38. 2011
  5. ncbi Novel treatments and future perspectives: outcomes of intrathecal drug delivery
    P I Dickson
    Division of Medical Genetics, Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Int J Clin Pharmacol Ther 47:S124-7. 2009
  6. ncbi Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I
    Patricia I Dickson
    Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Mol Genet Metab 101:115-22. 2010
  7. ncbi Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase
    Agnes Chen
    Division of Pediatric Neurology, Department of Pediatrics, LABioMed at Harbor UCLA Medical Center, Torrance, CA 90509, USA
    APMIS 119:513-21. 2011
  8. ncbi Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I
    Patricia Dickson
    Division of Medical Genetics, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California, USA
    J Clin Invest 118:2868-76. 2008
  9. ncbi Hereditary multiple exostoses with spine involvement in a 4-year-old boy
    Navid Ezra
    David Geffen School of Medicine at UCLA, Los Angeles, CA 90509, USA
    Am J Med Genet A 152:1264-7. 2010
  10. ncbi Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression
    María Verónica Muñoz-Rojas
    Hospital de Clinicas de Porto Alegre, Medical Genetics Service, Porto Alegre, Brazil
    Am J Med Genet A 146:2538-44. 2008

Research Grants

  1. Intrathecal enzyme therapy for mucopolysaccharidosis I
    Patricia Dickson; Fiscal Year: 2007
  2. Pilot/Phase I Study of Intrathecal Laronidase for Spinal Cord Compression in Muco
    Patricia Dickson; Fiscal Year: 2009
  3. Intrathecal enzyme therapy for mucopolysaccharidosis I
    Patricia I Dickson; Fiscal Year: 2010

Collaborators

Detail Information

Publications10

  1. ncbi Costello syndrome with pancreatic islet cell hyperplasia
    Patricia I Dickson
    Division of Medical Genetics, Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Am J Med Genet A 130:402-5. 2004
    ..Clinical similarities among these disorders and CS, together with the finding of islet cell hyperplasia, suggest that they may be related...
  2. ncbi Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid
    Patricia Dickson
    Division of Medical Genetics, Department of Pediatrics, LA Biomed at Harbor UCLA, Torrance, CA 90502, USA
    Mol Genet Metab 91:61-8. 2007
    ..The improvement in GAG storage levels persisted three months after the final IT dose. The successful use of enzyme therapy via the CSF represents a potentially useful approach for lysosomal storage disorders...
  3. ncbi Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients
    Patricia I Dickson
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Curr Pharm Biotechnol 12:946-55. 2011
    ....
  4. ncbi Research challenges in central nervous system manifestations of inborn errors of metabolism
    P I Dickson
    Department of Pediatrics, LA Biomedical Research Institute at Harbor UCLA, 1124 W Carson St, HH1, Torrance, CA 90502, USA
    Mol Genet Metab 102:326-38. 2011
    ..Scientific, ethical and regulatory issues are discussed, along with ways to measure outcomes and the conduct of clinical trials. Participants included regulatory and funding agencies, clinicians, scientists, industry and advocacy groups...
  5. ncbi Novel treatments and future perspectives: outcomes of intrathecal drug delivery
    P I Dickson
    Division of Medical Genetics, Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Int J Clin Pharmacol Ther 47:S124-7. 2009
    ..Studies are underway to investigate the safety and efficacy of intrathecal ERT in patients with MPS I...
  6. ncbi Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I
    Patricia I Dickson
    Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Mol Genet Metab 101:115-22. 2010
    ..High-dose IV rhIDU from birth (1.57mg/kg weekly) appeared to prevent cord compression due to protrusion of spinal disks...
  7. ncbi Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase
    Agnes Chen
    Division of Pediatric Neurology, Department of Pediatrics, LABioMed at Harbor UCLA Medical Center, Torrance, CA 90509, USA
    APMIS 119:513-21. 2011
    ..Response to therapy appeared to be greater in more superficial regions of the brain, particularly in the frontal lobe cortex...
  8. ncbi Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I
    Patricia Dickson
    Division of Medical Genetics, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California, USA
    J Clin Invest 118:2868-76. 2008
    ....
  9. ncbi Hereditary multiple exostoses with spine involvement in a 4-year-old boy
    Navid Ezra
    David Geffen School of Medicine at UCLA, Los Angeles, CA 90509, USA
    Am J Med Genet A 152:1264-7. 2010
    ..His affected sibling also displayed spinal cord compression because of a bony exostosis. Acute cervical spinal cord compression resulting from osteochondroma is a serious complication of HME. (c) 2010 Wiley-Liss, Inc...
  10. ncbi Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression
    María Verónica Muñoz-Rojas
    Hospital de Clinicas de Porto Alegre, Medical Genetics Service, Porto Alegre, Brazil
    Am J Med Genet A 146:2538-44. 2008
    ..6% of predicted %. In conclusion, although the improvement observed in this case with IT laronidase should be confirmed in further patients, this procedure seems to be a safe treatment for SCC in MPS I...

Research Grants7

  1. Intrathecal enzyme therapy for mucopolysaccharidosis I
    Patricia Dickson; Fiscal Year: 2007
    ..This research investigates intrathecal enzyme therapy for canine MRS I with translation to the first clinical trial of intrathecal enzyme replacement therapy for MRS I patients. ..
  2. Pilot/Phase I Study of Intrathecal Laronidase for Spinal Cord Compression in Muco
    Patricia Dickson; Fiscal Year: 2009
    ..If successful, delivery into the spinal fluid could represent a practical, straightforward method of treating central nervous system disease due to lysosomal storage. ..
  3. Intrathecal enzyme therapy for mucopolysaccharidosis I
    Patricia I Dickson; Fiscal Year: 2010
    ..This research investigates intrathecal enzyme therapy for canine MRS I with translation to the first clinical trial of intrathecal enzyme replacement therapy for MRS I patients. ..